Supplementary Material for: Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complication of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatment and follow-up. To develop a reasonable, long-term, and complete management plan, multiple factors need to be considered, including the patient's general condition, basic liver diseases, tumor stage, tumor biological characteristics, treatment requirements and economic cost. Summary: To better guide the whole-course management of HCC patients, the Chinese Association of Liver Cancer and the Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the “Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023).” Key Messages: This expert consensus, based on the current clinical evidence and experience, proposes surgical and nonsurgical HCC management pathways and involves 18 recommendations, including perioperative treatment, systematic treatment combined with local treatment, conversion treatment, special population management, symptomatic support treatment, and follow-up management.背景：肝细胞癌（Hepatocellular carcinoma, HCC）是我国最常见的恶性肿瘤之一。多数肝细胞癌患者合并慢性肝脏疾病，需开展综合评估与全流程管理，涵盖诊断、治疗及随访环节。制定合理、长期且完整的管理方案时，需综合考量多维度因素，包括患者一般状况、基础肝病情况、肿瘤分期、肿瘤生物学特征、治疗需求与经济成本。概述：为更好地指导肝细胞癌患者的全流程管理，中国肝癌协会（Chinese Association of Liver Cancer）与中国医师协会（Chinese Medical Doctor Association）组织相关领域多学科专家学者，制定了《肝细胞癌全流程管理中国专家共识（2023版）》。核心要点：本专家共识基于当前临床证据与实践经验，提出了肝细胞癌手术与非手术管理路径，共包含18条推荐意见，涵盖围手术期治疗、系统治疗联合局部治疗、转化治疗、特殊人群管理、症状支持治疗以及随访管理等内容。